Pioneers genome editing technologies to develop CAR-T cell therapies for cancer treatment.
Cellectis S.A., a pioneering clinical-stage biotechnology company, specializes in developing innovative immuno-oncology products centered around gene-edited T-cells engineered to express chimeric antigen receptors (CAR-T) for precise targeting and elimination of cancer cells. The company operates through two distinct segments: Therapeutics and Plants.
Cellectis is advancing a robust pipeline of therapeutic candidates. This includes UCART19, an allogeneic T-cell product designed to treat CD19-expressing hematologic malignancies like acute lymphoblastic leukemia. Additionally, the company is developing ALLO-501 and ALLO-501A for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma, ALLO-316 targeting Renal Cell Carcinoma, UCART123 for acute myeloid leukemia, and UCART22 for B-cell acute lymphoblastic leukemia. Further, Cellectis is exploring UCARTCS1 and ALLO-715 for multiple myeloma treatment.
Founded in 1999 and headquartered in Paris, France, Cellectis S.A. has forged strategic alliances with prominent entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, Iovance Biotherapeutics, and collaborative research and development agreements with Cytovia Therapeutics, Inc. and Primera Therapeutics, Inc. These partnerships underscore Cellectis' commitment to advancing cutting-edge CAR-T therapies, positioning itself at the forefront of the biotechnological revolution in oncology treatment.